Product Description: Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].
Applications: Cancer-Kinase/protease
Formula: C26H23FIN5O4
Citations: ACS Comb Sci. 2019 Dec 9;21(12):805-816./Acta Pharmacol Sin. 2023 Feb 1./Adv Healthc Mater. 2024 Oct 14:e2402685./Adv Sci (Weinh). 2023 Mar 8;e2201164./Am J Digest Dis. 2015;2(2):95-99./Am J Respir Cell Mol Biol. 2019 Sep;61(3):355-366./Anal Chem. 2024 Mar 8./Angiogenesis. 2024 Jul 5./Aquaculture. 2023 Sep 23, 740148./Aquaculture. 2024 Oct 15./Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489./Biochem Biophys Res Commun. 2018 Jan 8;495(2):1846-1850. /Biomaterials. 16 September 2022./Biomaterials. 2018 Sep;178:158-169./Biomolecules. 2021 Mar 30;11(4):518./Biomolecules. 2023 Apr 25, 13(5), 740./bioRxiv. 2019 Sep./bioRxiv. 2023 Oct 23./bioRxiv. 2023 Oct 6./bioRxiv. 2023 Sep 3./bioRxiv. 2023 Sep 8./bioRxiv. 2024 August 09./bioRxiv. 2024 Dec 5:2024.11.29.625709./bioRxiv. 2024 November 03./bioRxiv. 2024 November 28./bioRxiv. 2024 October 26./bioRxiv. 2024 September 04./bioRxiv. 2024 September 19./bioRxiv. 2024 September 23./Blood Cancer J. 2024 Aug 19;14(1):138./Br J Cancer. 2023 May 17./Cancer Biol Ther. 2019;20(5):653-665./Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8./Cancer Cell. 2021 May 10;39(5):678-693.e11./Cancer Cell. 2023 Dec 11;41(12):2083-2099.e9./Cancer Cell. 2024 Jul 8;42(7):1286-1300.e8./Cancer Discov. 2012 Oct;2(10):934-47./Cancer Discov. 2015 Sep;5(9):960-71./Cancer Discov. 2018 Mar;8(3):354-369./Cancer Discov. 2020 Aug;10(8):1226-1239./Cancer Discov. 2020 Jun;10(6):872-887./Cancer Immunol Res. 2020 Dec 10./Cancer Lett. 2017 Nov 1;408:43-54. /Cancer Lett. 2024 Jun 5:217007./Cancer Res. 2022 May 18;canres.4152.2021./Cancer Res. 2024 Aug 13./Cancers (Basel). 2022 Mar 11;14(6):1451./Cancers (Basel). 2023 Apr 13, 15(8), 2280./Cancers (Basel). 2024 Aug 7;16(16):2785./Cancers. 2021 Feb 2;13(3):581./Cell Biol Int. 2024 Sep 24./Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4./Cell Death Differ. 2020 May;27(5):1520-1538. /Cell Death Dis. 2022 Oct 3;13(10):844./Cell Death Dis. 2024 Nov 13;15(11):821./Cell Death Discov. 2023 Sep 19;9(1):347./Cell Metab. 2019 Jan 8;29(1):141-155.e9. /Cell Mol Life Sci. 2023 Mar 18;80(4):100./Cell Oncol. 2022 Oct 21./Cell Rep. 2019 Jul 2;28(1):119-131.e4. /Cell Signal. 2024 Sep 16:111415./Cell Syst. 2019 Jul 24;9(1):35-48.e5. /Cell Syst. 2020 Jan 22;10(1):66-81.e11./Cell Syst. 2020 Nov 18;11(5):478-494.e9./Cell. 2024 Feb 1;187(3):624-641.e23./Cell. 2024 Jan 4;187(1):166-183.e25./Cell. 2018 Aug 9;174(4):843-855.e19./Cells. 2022, 11(15), 2402./Clin Cancer Res. 2014 Nov 1;20(21):5483-95. /Clin Cancer Res. 2022 Jul 7;ccr.22.1052./Clin Cancer Res. 2023 Jan 17;CCR-22-1973./Comput Struct Biotechnol J. 2019 Feb 8;17:352-361./Dis Model Mech. 2023 Mar 2;dmm.049769./EBioMedicine. 2020 Jan;51:102583./EBioMedicine. 2022 Dec 8;87:104397./Endocrinology. 2024 Sep 16./Eur J Cancer. 2018 Aug;99:37-48./Exp Cell Res. 2020 Aug 1;393(1):112054./Exp Mol Med. 2023 Oct 2./FEBS Lett. 2024 Oct 20./Front Cell Dev Biol. 2018 Sep 25;6:111./Front Oncol. 2021 Jul 13;11:704042./Genes Dis. 1 July 2021./Geroscience. 2023 Sep 26./Harvard Medical School LINCS LIBRARY/Inflammation. 2023 May 12./Int J Cancer. 2019 Mar 15;144(6):1379-1390./Int J Mol Sci. 2022 Nov 19;23(22):14385./Int J Mol Sci. 2022, 23(19), 11939./Int J Mol Sci. 2022, 23(20), 12587./Int J Mol Sci. 2023 Mar 13./J Cardiothorac Surg. 2021 May 10;16(1):127./J Cell Biochem. 2016 Jun;117(6):1340-51. /J Cell Sci. 2019 May 31;132(11):jcs224071. /J Clin Invest. 2022 Nov 22;e153470./J Clin Toxicol 2014, 4:5/J Clin Toxicol. 2014 October 4, 4:5./J Exp Clin Cancer Res. 2018 Sep 5;37(1):218./J Exp Clin Cancer Res. 2023 Apr 19;42(1):92./J Exp Clin Cancer Res. 2024 Jun 18;43(1):171./J Exp Med. 2024 Mar 4;221(3):e20232028./J Hepatol. 2021 Aug;75(2):363-376./J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9./J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8./J Transl Med. 2022 Jun 7;20(1):263./J Transl Med. 2023 Jan 9;21(1):9./J Transl Med. 2024 May 13;22(1):450./J Vasc Res. 2023 Feb 2./JCO Precis Oncol. 2024 Apr:8:e2300538./Leuk Lymphoma. 2021 Feb;62(2):337-347./Mbio. 2024 Jan 23:e0319723./medRxiv. 2023 Nov 13./Mil Med Res. 2023 Dec 20;10(1):68./Mol Cancer Ther. 2016 Aug;15(8):1859-69. /Mol Cancer. 2023 May 20;22(1):86./Mol Cancer. 2024 Sep 20;23(1):204./Mol Carcinog. 2024 Apr 17/Mol Pharmacol. 2019 Dec;96(6):862-870./Mol Psychiatry. 2022 Aug 10./Mol Syst Biol. 2023 Dec 18./Mol Ther Nucleic Acids. 2024 Jul 19;35(3):102283./Nat Biomed Eng. 2018 Aug;2(8):578-588./Nat Cell Biol. 2023 Jan 12./Nat Commun. 2020 Aug 13;11(1):4053./Nat Commun. 2020 May 11;11(1):2333./Nat Commun. 2020 Oct 29;11(1):5463./Nat Commun. 2021 Aug 25;12(1):5058./Nat Commun. 2023 May 19;14(1):2859./Nat Commun. 2024 Mar 21;15(1):2551./Nat Commun. 2024 May 7;15(1):3805./Nat Commun. 2019 Jan 17;10(1):296./Neuro Oncol. 2019 Mar 18;21(4):486-497. /Oncogene. 2024 May 17./Oncogenesis. 2019 Nov 4;8(11):65. /Oncol Lett. 2017 Dec;14(6):6863-6868./Oncol Lett. December 17, 2021./Oncol Rep. 2018 Dec; 40(6): 3313–3322./Oncotarget. 2015 Oct 13;6(31):31313-22. /Oncotarget. 2017 Feb 28;8(9):14835-14846. /Oncotarget. 2020 Nov 3;11(44):3921-3932./Patent. US20180161326A1./Patent. US20180169102A1./Patent. US20180291421A1./Patent. US20200276189A1./Patent. US20200291111A1./Patent. US20200308623A1./Patent. US20200354680A1./Patent. US20210008047A1./Patent. US20210010089A1./Patent. US20220265657A1./Patent. US20220372134A1./Patent. US20230049752A1./Patent. US20230068698A1./Patent. US20230158019A1./Patent. US20240140945A1./Patent. US20240239801A1./Patent. US20240366605A1/Patent. US20240366605A1./Patent. WO2019056023A2./Phytomedicine. 2023 Nov 11, 155208./PLoS Biol. 2020 Jul 17;18(7):e3000778./Preprints. 2024 Jul 8./Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9570-E9579. /Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4508-4517./Research Square Preprint. 2020 Jun./Research Square Preprint. 2021 Oct./Research Square Preprint. 2023 Jul 10./Research Square Preprint. 2023 May 16./Research Square Preprint. 2024 Nov 03./Research Square Preprint. 2024 Nov 06./Research Square Preprint. 2024 Nov 26./Research Square Preprint. 2024 Oct 10./Research Square Print. October 10th, 2022./Sci Data. 2024 Sep 19./Sci Rep. 2016 Oct 19;6:35531./Sci Rep. 2017 Mar 28;7:45332./Sci Rep. 2022 Nov 5;12(1):18811./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Sci Transl Med. 2021 Jan 27;13(578):eaba7308./SSRN. 2023 Aug 9./Stem Cell Reports. 2016 Jan 12;6(1):74-84./Stem Cell Reports. 2017 Dec 12;9(6):1948-1960./Technical University of Munich. 2024./Theranostics. 2022 Oct 3;12(16):7051-7066./Theranostics. 2020 Feb 18;10(8):3579-3593. /Toxicology. 2024 Apr 17:153807./University of California. 2023 Feb./University of Düsseldorf. 2024./University of Puerto Rico. 2024 Jun./Vet J. 2024 Dec./Viruses. 2021, 13(9), 1758./Cancer Cell. 2020 Mar 16;37(3):387-402.e7. /Cell Rep. 2021 Jul 20;36(3):109410./Cell Rep. 2023 Dec 18;42(12):113586./Faculty of Biology, University of Barcelona. 2020 Jan./Mol Cell. 2019 Jan 3;73(1):7-21.e7. /Patent. US20200046706A1./Patent. US20210401844A1./Patent. US20220162299A1./Patent. US20220177583A1./PLoS One. 2020 Sep 3;15(9):e0235824./Sci Signal. 2018 Oct 30;11(554):eaar6795./University of Leicester. 2023 Sep.
References: [1]Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61(5), 445-454./[2]Yamaguchi T, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol, 2011, 39(1), 23-31./[3]Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011 Feb 28;2(4):320-4./[4]Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369./[5]Lai J, et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials. 2018 Sep;178:158-169.
CAS Number: 871700-17-3
Molecular Weight: 615.39
Compound Purity: 99.96
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;Autophagy;MEK
Deutsch
English
